Unveiling the anti-tumor and anti-fibrotic potentials of Kanglaite in esophageal cancer through PVT1/TGF-β/Smad axis inhibition

Main Article Content

Xiuqing Li
Ka Bian
Ji Zhang
Kaili Luo
Tao Dong
Chenglin Luo


esophageal cancer, fibrosis, Kanglaite, plasmacytoma variant translocation 1, TGF-β/Smad pathway


Esophageal cancer (EC) poses a significant challenge among tract tumors worldwide due to its complex molecular composition, which remains largely unexplored. Kanglaite (KLT), a medicine known for its anti-tumor properties, is emerging as a potential ally in the culinary world. Plasmacytoma Variant translocation 1 (PVT1) plays a significant role in the complex nature of esophageal cancer, showing high expression levels in tumor tissues. During our investigation, we discovered a higher presence of PVT1 in cancer tissues, which led us to explore its functions further. Through manipulating techniques, we found that inhibiting PVT1 not only hinders the growth of esophageal cancer cells but also reduces fibrosis. This is similar to enhancing the texture and flavor of a dish. Our study reveals the interactions at play, highlighting how PVT1 orchestrates the TGF β/Smad pathway – a component in the development of esophageal cancer. Introducing KLT, an expert poised to revolutinize the approach to cancer treatment. Our research demonstrates KLT’s effectiveness in regulating the PVT1/TGF-β/Smad axis, uncovering its fibrotic properties, and its ability to hinder the progression of esophageal cancer. With these discoveries, KLT emerges as a promising option for the treatment of esophageal cancer.

Abstract 55 | PDF Downloads 22 HTML Downloads 0 XML Downloads 5


Chen, C., Ai, Q. D., & Wei, Y. H. (2021). Kanglaite enhances the efficacy of cisplatin in suppression of hepatocellular carcinoma via inhibiting CKLF1 mediated NF-kappaB pathway and regulating transporter mediated drug efflux. Journal of Ethnopharmacology, 264, 113388. 10.1016/j.jep.2020.113388

Dong, L., Wang, H., Gao, Y., Wang, S., & Wang, W. (2023). Long non-coding RNA PVT1 promotes the proliferation, migration and EMT process of ovarian cancer cells by regulating CTGF. Oncology Letters, 25(2), 71. 10.3892/ol.2022.13657

Kashiwagi, M., Ojima, T., Hayata, K., Kitadani, J., Takeuchi, A., Kuroi, A., et al. (2023). Impact of pulmonary vein anatomy and left atrial size on postoperative atrial fibrillation after esophagectomy for esophageal cancer. Esophagus, 20(4), 626–634. 10.1007/s10388-023-01018-8

Li, Z., Li, M., Xia, P., Wang, L., & Lu, Z. (2022). Targeting long non-coding RNA PVT1/TGF-beta/Smad by p53 prevents glioma progression. Cancer Biology & Therapy, 23(1), 225–233. 10.1080/15384047.2022.2042160

Lian, J., Xu, A., Chen, T., Zhang, H., & Xu, M. (2023). Unexpected gastric perforation during endoscopic submucosal tunnel dissection for early circumferential esophageal cancer. Endoscopy, 55(S 01), E833–E834. 10.1055/a-2106-1012

Liu, H., Ma, X. F., Dong, N., Wang, G. N., Qi, M. X., & Tan, J. K. (2024). LncRNA PVT1 inhibits endothelial cells apoptosis in coronary heart disease through regulating MAPK1 expression via miR-532-3p. Acta Cardiologica, 79(3), 295–303. 10.1080/00015385.2023.2209448

Liu, L., Huan, L., Zhang, Y., Wei, W., Chen, Z., Xu, D., et al. (2022). Ubiquitin-specific protease 8 inhibits lipopolysaccharide-triggered pyroptosis of human bronchial epithelial cells by regulating PI3K/AKT and NF-kappaB pathways. Allergol Immunopathol (Madr), 50(2), 96–103. 10.15586/aei.v50i2.568

Luan, Y., Luan, Y., Feng, Q., Chen, X., Ren, K. D., & Yang, Y. (2021a). Emerging role of mitophagy in the heart: Therapeutic potentials to modulate mitophagy in cardiac diseases. Oxidative Medicine and Cellular Longevity, 2021, 3259963. 10.1155/2021/3259963

Luan, Y., Ren, K. D., Luan, Y., Chen, X., & Yang, Y. (2021b). Mitochondrial dynamics: Pathogenesis and therapeutic targets of vascular diseases. Frontiers in Cardiovascular Medicine, 8, 770574. 10.3389/fcvm.2021.770574

Luo, Z., Chen, R., Hu, S., Huang, X., & Huang, Z. (2022). PVT1 promotes resistance to 5-FU in colon cancer via the miR-486-5p/CDK4 axis. Oncology Letters, 24(2), 280. 10.3892/ol.2022.13400

Lv, P., & Liu, M. (2023). Meta-analysis of the clinical effect of Kanglaite injection-assisted gemcitabine plus cisplatin regimen on non-small cell lung cancer. American Journal of Translational Research, 15(5), 2999–3012.

Rasouli, S., Heshmatnia, J., Mosaffa, N., Marjani, M., & Mortaz, E. (2023). Dysregulation of immunity in pulmonary fibrosis is associated with increased myeloid-specific triggering receptor-1 and transforming growth factor-beta1 expression. Iranian Journal of Allergy, Asthma, and Immunology, 22(1), 12–24. 10.18502/ijaai.v22i1.12002

Shi, G., Zheng, X., Zhang, S., Wu, X., Yu, F., Wang, Y., et al. (2018). Kanglaite inhibits EMT caused by TNF-alpha via NF-kappaBeta inhibition in colorectal cancer cells. Oncotarget, 9(6), 6771–6779. 10.18632/oncotarget.23645

Sun, C., Ye, Y., Tan, Z., Liu, Y., Li, Y., Hu, W., et al. (2023). Tumor-associated nonmyelinating Schwann cell-expressed PVT1 promotes pancreatic cancer kynurenine pathway and tumor immune exclusion. Science Advances, 9(5), eadd6995. 10.1126/sciadv.add6995

Sun, J., Sun, Y., Miniderima, & Wang, X. (2023). Cytokine-induced killer cell treatment is superior to chemotherapy alone in esophageal cancer. Pathology Oncology Research, 29, 1610710. 10.3389/pore.2023.1610710

Tang, P. C., Zhang, Y. Y., Li, J. S., Chan, M. K., Chen, J., Tang, Y., et al. (2022). LncRNA-dependent mechanisms of transforming growth factor-beta: From tissue fibrosis to cancer progression. Non-coding RNA, 8(3), 26. 10.3390/ncrna8030036

Wang, P., Chen, C., Zhang, Q. H., Sun, G. D., Wang, C. A., & Li, W. (2021). Retraction of lumbar disc herniation achieved by noninvasive techniques: A case report. World Journal of Clinical Cases, 9(27), 8082–8089. 10.12998/wjcc.v9.i27.8082

Wu, B. Q., Jiang, Y., Zhu, F., Sun, D. L., & He, X. Z. (2017). Long noncoding RNA PVT1 promotes EMT and cell proliferation and migration through downregulating p21 in pancreatic cancer cells. Technology in Cancer Research & Treatment, 16(6), 819–827. 10.1177/1533034617700559

Yanagida, M., Hosoi, Y., Kawano, T., Otake, Y., Yamanaka, Y., Baba, T., et al. (2024). Noniatrogenic meningitis caused by Streptococcus salivarius associated with early esophageal cancer and early gastric cancer. Internal Medicine, 63(3), 457–460. 10.2169/internalmedicine.1304-22

Yang, C., Hou, A., Yu, C., Dai, L., Wang, W., Zhang, K., et al. (2018). Kanglaite reverses multidrug resistance of HCC by inducing apoptosis and cell cycle arrest via PI3K/AKT pathway. OncoTargets and Therapy, 119, 83–96. 10.2147/OTT.S153814

Yang, X. X., Ma, M., Sang, M. X., Zhang, X. Y., Zou, N. Y., & Zhu, S. C. (2020). Knockdown of FAM83D enhances radiosensitivity in coordination with irradiation by inhibiting EMT via the Akt/GSK-3beta/Snail signaling pathway in human esophageal cancer cells. OncoTargets and Therapy, 13, 4665–4678. 10.2147/OTT.S245681

Yang, Y. M., Hong, P., Xu, W. W., He, Q. Y., & Li, B. (2020). Advances in targeted therapy for esophageal cancer. Signal Transduction and Targeted Therapy, 5(1), 229. 10.1038/s41392-020-00323-3

Zhang, P., Gong, S., Li, S., & Yuan, Z. (2023). PVT1 alleviates hypoxia-induced endothelial apoptosis by enhancing autophagy via the miR-15b-5p/ATG14 and miR-424-5p/ATG14 axis. Biochemical and Biophysical Research Communications, 67, 11–19. 10.1016/j.bbrc.2023.06.001

Zhang, X. W., Liu, L., Zhang, X. Z., & Bo, P. (2017). Kanglaite inhibits the expression of drug resistance genes through suppressing PVT1 in cisplatin-resistant gastric cancer cells. Experimental and Therapeutic Medicine, 14(2), 1789–1794. 10.3892/etm.2017.4650

Zhao, M., Fu, L., Xu, P., Wang, T., & Li, P. (2023). Network pharmacology and experimental validation to explore the effect and mechanism of Kanglaite injection against triple-negative breast cancer. Drug Design, Development and Therapy, 17, 901–917. 10.2147/DDDT.S397969

Zheng, X., Hu, H., & Li, S. (2016). High expression of lncRNA PVT1 promotes invasion by inducing epithelial-to-mesenchymal transition in esophageal cancer. Oncology Letters, 12(4), 2357–2362. 10.3892/ol.2016.5026